ReviewVascular health and risk management2017
Evaluation of bleeding in patients receiving direct oral anticoagulants.
Review in Vascular health and risk management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06168838 (Anticoagulant-associated Intracranial Hemorrhage), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Pooled it
- Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis.European journal of clinical pharmacology · 2022Pooled it
- Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial.Arteriosclerosis, thrombosis, and vascular biology · 2024Trial
- Agent-specific bleeding signatures in non-hypertensive versus hypertensive patients exposed to oral anticoagulants: a real-world pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Comparison of monthly bleeding rates after direct oral anticoagulant initiation for venous thromboembolism and atrial fibrillation.Research and practice in thrombosis and haemostasis · 2026Article
- Prothrombin complex concentrate for oral factor Xa inhibitor-associated intracerebral hemorrhage.Research and practice in thrombosis and haemostasis · 2026Article
- Targeting factor XI as a compromise between thrombosis and bleeding.Cardiology journal · 2025Review
- The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo.Journal of thrombosis and thrombolysis · 2024Article
- Venous thromboembolism treatment failure during use of factor Xa inhibitors-association with thoracic outlet syndrome and development of chronic thromboembolic pulmonary hypertension.Annals of medicine · 2024Observational
- Discovery of Heparin Mimetic, Potent, and Selective Inhibitors of Human Clotting Factor XIIIa.ACS omega · 2024Article
- Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Review
- Medication errors in relation to direct-acting oral anticoagulants: a qualitative study of pharmacists' views and experiences.International journal of clinical pharmacy · 2023Article
- Article
- All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a protocol for a systematic review and meta-analysis.Systematic reviews · 2022Article
- Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease.Journal of cardiovascular development and disease · 2022Review
- Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen.Journal of thrombosis and haemostasis : JTH · 2022Article
- Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.Chemical biology & drug design · 2022Article
- Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries.Journal of clinical medicine · 2022Article
- Evaluation of two European risk models for predicting medication harm in an Australian patient cohort.European journal of clinical pharmacology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding-related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real-world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.